Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US. They've registered Striate+ as the new global brand for the CelGro dental bone and tissue regeneration product and the company will market the procedure in the US under this brand.
Orthocell's Paul Anderson hails FDA approval for dental bone and tissue regeneration product
